Highly ordered mesoporous carbon nanomatrix as a new approach to improve the oral absorption of the water-insoluble drug, simvastatin

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 5, 2013, Pages 864-872

  Zhang, Yanzhuo ^a   Wang, Huan ^b   Gao, Cunqiang ^c   Li, Xue ^b   Li, Lusi ^c  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c Jiangsu Hengrui Medicine Co Ltd   (China)

Author keywords

Bioavailability; Crystalline state; Mesoporous carbon; Nanomatrix; Solubility; Water insoluble drugs

Indexed keywords

CARBON NANOTUBE; DRUG CARRIER; HIGHLY ORDERED MESOPOROUS CARBON; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIATION SCATTERING; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84885063140     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.031     Document Type: Article

References (43)

1. Ambrogi, V., Perioli, L., Marmottini, F., Giovagnoli, S., Esposito, M., Rossi, C., 2007. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur. J. Pharm. Sci. 32, 216-222. (Pubitemid 47532714)
2. Ambrogi, V., Perioli, L., Marmottini, F., Accorsi, O., Paganoa, C., Riccia, M., Rossi, C., 2008. Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Micropor. Mesopor. Mater. 113, 445-452.
3. Barbé, C., Bartlett, J., Kong, L., Finnie, K., Lin, H.Q., Larkin, M., Calleja, S., Bush, A., Calleja, G., 2004. Silica particles: a novel drug-delivery system. Adv. Mater. 16, 1949-1966.
4. Bastin, R.J., Bowker, M.J., Slater, B.J., 2000. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Proc. Res. Dev. 4, 427-435.
5. Blagden, N., Matas, M., Gavan, P.T., York, P., 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59, 617-630. (Pubitemid 47285407)
6. Cauda, V., Muhlstein, L., Onida, B., Bein, T., 2009. Tuning drug uptake and release rates through different morphologies and pore diameters of confined mesoporous silica. Micropor. Mesopor. Mater. 118, 435-443.
7. Charnay, C., Bégu, S., Tourné-Péteilh, C., Nicole, L., Lerner, D.A., Devoisselle, J.M., 2004. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur. J. Pharm. Biopharm. 57, 533-540. (Pubitemid 38490572)
8. Graeser, K.A., Strachan, C.J., Patterson, J.E., Gordon, K.C., Rades, T., 2008. Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Cryst. Growth Des. 8, 128-135.
9. Heikkilä, T., Salonen, J., Tuura, J., Hamdy, M.S., Mul, G., Kumar, N., Salmi, T., Murzin, D.Y., Laitinen, L., Kaukonen, A.M., Hirvonen, J., Lehto, V.P., 2007. Mesoporous silica material TUD-1 as a drug delivery system. Int. J. Pharm. 331, 133-138. (Pubitemid 46176505)
10. Hörter, D., Dressman, J.B., 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46, 75-87.
11. Huanga, L.F., Tong, W.Q.T., 2004. Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Del. Rev. 56, 321-334.
12. Illingworth, D.R., Tobert, J.A., 2000. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16, 1004-1010.
13. Jaganathan, H., Godin, B., 2012. Biocompatibility assessment of Si-based nano-and micro-particles. Adv. Drug Deliv. Rev. 64, 1800-1819.
14. Jia, L., Shen, J., Li, Z., Zhang, D., Zhang, Q., Duan, C., Liu, G., Zheng, D., Liu, Y., Tian, X., 2012. Successfully tailoring the pore size of mesoporous silica nanoparticles exploitation of delivery systems for poorly water-soluble drugs. Int. J. Pharm. 439, 81-91.
15. Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv. Drug Del. Rev. 59, 631-644. (Pubitemid 47285408)
16. Kim, T.W., Slowing, I.I., Chung, P.W., Lin, V.S.Y., 2011. Ordered mesoporous polymersilica hybrid nanoparticles as vehicles for the intracellular controlled release of macromolecules. ACS Nano. 5, 360-366.
17. Lee, H.I., Kim, J.H., You, D.J., Lee, J.E., Kim, J.M., Ahn, W.S., Pak, C., Joo, S.H., Chang, H., Seung, D., 2008. Rational synthesis pathway for ordered mesoporous carbon with controllable 30-to 100-angstrom pores. Adv. Mater. 20, 757-762.
18. Li, Y., Wang, T., Wang, J., Jiang, T., Cheng, G., Wang, S., 2011. Functional and unmodified MWNTs for delivery of the water-insoluble drug carvedilol-a drug-loading mechanism. Appl. Surf. Sci. 257, 5663-5670.
19. Liang, C., Li, Z., Dai, S., 2008. Mesoporous carbon materials: synthesis and modification. Angew. Chem. 47, 3696-3717.
20. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Deliv. Rev. 23, 3-25. (Pubitemid 27046991)
21. Liu, R., Shi, Y., Wan, Y., Meng, Y., Zhang, F., Gu, D., Chen, Z., Tu, B., Zhao, D., 2006. Triconstituent co-assembly to ordered mesostructured polymer-silica and carbon-silica nanocomposites and large-pore mesoporous carbons with high surface areas. J. Am. Chem. Soc. 128, 11652-11662. (Pubitemid 44338857)
22. Liu, R., Wang, X., Zhao, X., Feng, P., 2008. Sulfonated ordered mesoporous carbon for catalytic preparation of biodiesel. Carbon 46, 1664-1669.
23. Liu, X., Li, L., Du, Y., Guo, Z., Ong, T.T., Chen, Y., Ng, S.C., Yang, Y., 2009. Synthesis of large pore-diameter SBA-15 mesostructured spherical silica and its application in ultra-high-performance liquid chromatography. J. Chromatogr. A 1216, 7767-7773.
24. Manly, C.J., Louise-May, S., Hammer, J.D., 2007. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov. Today 6, 1101-1110.
25. Mellaerts, R., Mols, R., Jammaer, J.A.G., Aerts, C.A., Annaert, P., Humbeeck, J.V., Mooter, G.V., Augustijns, P., Martens, J.A., 2008. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm. 69, 223-230.
26. Qian, K.K., Bogner, R.H., 2011. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J. Pharm. Sci. 101, 444-463.
27. Sadighi, A., Ostad, S.N., Rezayat, S.M., Foroutan, M., Faramarzie, M.A., Dorkoosh, F.A., 2012. Mathematical modelling of the transport of hydroxypropyl-βcyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Int. J. Pharm. 17, 479-488.
28. Salonen, J., Laitinen, L., Kaukonen, A.M., Tuura, J., Björkqvist, M., Heikkilä, T., Vähä-Heikkilä, K., Hirvonen, J., Lehto, V.P., 2005. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J. Control. Release 108, 362-374. (Pubitemid 41608668)
29. Tan, A., Davey, A.K., Prestidge, C.A., 2011. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharm. Res. 28, 2273-2287.
30. Tang, F., Li, L., Chen, D., 2012. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 24, 1504-1534.
31. Thomas, M.J.K., Slipper, I., Walunj, A., Jain, A., Favretto, M.E., Kallinteri, P., Douroumis, D., 2009. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int. J. Pharm. 387, 272-277.
32. Vasconcelos, T., Sarmento, B., Costa, P., 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12, 1068-1075. (Pubitemid 350186132)
33. Vashist, S.K., Zheng, D., Pastorin, G., Al-Rubeaan, K., Luongf, J.H.T., Sheua, F.S., 2011. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 49, 4077-4097.
34. Wang, S., 2009. Ordered mesoporous materials for drug delivery. Micropor. Mesopor. Mater. 117, 1-9.
35. Wang, F., Hui, H., Barnes, J., Barnett, C., Prestidge, C.A., 2009a. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol. Pharm. 7, 227-236.
36. Wang, Y., Zhang, F., Wang, Y., Ren, J., Li, C., Liu, X., Guo, Y., Lu, G., 2009b. Synthesis of length controllable mesoporous SBA-15 rods. Mater. Chem. Phys. 115, 649-655.
37. Wang, X., Liu, P., Tian, Y., 2011. Ordered mesoporous carbons for ibuprofen drug loading and release behavior. Micropor. Mesopor. Mater. 142, 366-385.
38. Wani, A., Muthuswamy, E., Savithra, G.H.L., Mao, G., Brock, S., Oupický, D., 2012. Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone. Pharm. Res. 29, 2407-2418.
39. Wu, C., Wang, Z., Zhi, Z., Jiang, T., Zhang, J., Wang, S., 2011. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int. J. Pharm. 403, 162-169.
40. Yang, P., Quan, Z., Lu, L., Huang, S., Lin, J., 2008. Luminescence functionalization of mesoporous silica with different morphologies and applications as drug delivery systems. Biomaterials 29, 692-702. (Pubitemid 350181037)
41. Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48, 27-42. (Pubitemid 32454482)
42. Zhang, Y., Wang, J., Bai, X., Jiang, T., Zhang, Q., Wang, S., 2012. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol. Pharm. 9, 505-513.
43. Zhao, D., Feng, J., Huo, Q., Melosh, N., Fredrickson, G.H., Chmelka, B.F., Stucky, G.D., 1998. Triblock copolymer syntheses of mesoporous silica with periodic 50-300 angstrom pores. Science 279, 548-552. (Pubitemid 28067280)